Replies to post #233307 on Biotech Values

[DewDiligence]

UCB.BR acquires ZGNX for $26.00/sh cash—a 66% premium to yesterday’s close:

https://finance.yahoo.com/news/ucb-acquire-zogenix-060000850.html

There is also a $2.00/sh (non-tradable) CVR based on EU approval of Fintepla by 12/31/23. (Fintepla was approved by the FDA in Jun 2020.)